MDSCs are a heterogeneous group of myeloid cells that suppress T cell activity in cancer and autoimmune disease. The effect of MDSCs on B cell function is not clear. Using the CIA model of autoimmune disease, we found an increase in M-MDSCs in the periphery of WT mice with CIA compared with naïve mice. These MDSCs were absent from the periphery of CCR2 mice from the exacerbated CIA phenotype and ameliorated disease in WT mice. Furthermore, adoptive transfer of M-MDSCs reduced autoantibody production by CCR2 2/2 and WT mice. In summary, M-MDSCs inhibit T cell and B cell function in CIA and may serve as a therapeutic approach in the treatment of autoimmune arthritis.
Introduction
MDSCs are a diverse group of immature cells that suppress T cell responses [1] . MDSCs are derived from the bone marrow and arise from a delay in maturation, prompted by pathologic conditions. Initially, MDSCs were defined as cells expressing CD11b and Gr-1 [2, 3] . As the Gr-1 + population of cells is composed of monocytic and granulocytic cells, MDSCs are now divided into 2 subsets: M-MDSCs, identified as CD11b 
Ly6C
+ Ly6G + cells [4, 5] . M-MDSC-mediated inhibition of T cell activities commonly results from up-regulation of iNOS expression, whereas G-MDSCs inhibit T cell function mainly through arginase-1 enzyme activity [6] .
Although much of what is known about the suppressive function of MDSCs was derived from studies of cancer patients and animal tumor models [7] , researchers have recently shown that MDSCs also play a role in autoimmune diseases. In an autoimmune hepatitis model, CD11b
+ Gr-1 + cells accumulated in the liver and suppressed CD4 + T cell responses [8] . An inflammatory bowel disease model showed that CD8 + T cell responses were inhibited in the intestines of diseased animals after administration of splenic MDSCs [9] . In EAE, the mouse model of multiple sclerosis, M-MDSCs and G-MDSCs were able to inhibit CD4 + T cell proliferation in vitro and ameliorated disease upon adoptive transfer [10, 11] . Whereas T cells are critical in autoimmune pathogenesis, B cells play a fundamental role in the initiation and perpetuation of autoimmunity [12, 13] . However, the impact of MDSCs on B cell function during the autoimmune process is not clear. Unraveling contributions of MDSCs to the regulation of autoimmunity will further the understanding of disease mechanisms and aid in the discovery of alternative approaches to treat autoimmune diseases. RA is an autoimmune disease that causes joint inflammation, cartilage damage, and bone erosion [14] . Our previous data revealed that a monocyte subset is absent in the periphery of CCR2 2/2 mice with CIA, an animal model of RA [15] . These mice developed an exacerbated arthritis phenotype compared with WT controls [15, 16] . Therefore, we hypothesized that the monocytes absent from CIA CCR2 
MATERIALS AND METHODS

Animals
DBA/1J mice (WT mice) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and bred and maintained in a pathogen-free facility. CCR2 2/2 mice on a DBA/1J background were generated by back-crossing CCR2 
CIA induction and evaluations
CIA was induced by immunization with CII (Chondrex, Redmond, WA, USA), emulsified with CFA (Sigma-Aldrich, St. Louis, MO, USA). The animals were given a booster dose of CII in IFA (Sigma-Aldrich) at Day 21 postimmunization. The immunization and disease evaluation methods were performed according to protocols validated previously by our group [15] with minor revisions. In brief, CII was dissolved in 0.1 M acetic acid and emulsified in an equal volume of CFA. On Day 0, mice were immunized by an s.c. injection of 100 ml emulsion containing 100 mg CII, ;1 cm from the base of the tail at Day 0. The clinical disease of arthritis was evaluated as follows: 0 = normal; 1 = swelling in 1 joint; 2 = swelling in .1 joint; 3 = swelling of the entire paw. Paw swelling was measured in the millimeter range with a dial thickness gauge (Geneva Gage, Albany, OR, USA). Arthritis scoring and measurement were performed in a blinded manner.
Bone marrow transplantation assay
Recipient DBA/1J mice (WT or CCR2
2/2
) received 9 Gy irradiation from a cesium source, 4 h before the adoptive transfer of 5 3 10 6 total bone marrow cells derived from WT or CCR2 2/2 DBA/1J mice. Bone marrow was harvested by flushing femurs with RPMI media containing 5% FBS and 2 mM EDTA. RBCs were lysed with lysis buffer (0.14 M NH 4 CI, 0.017 M Tris-HCl, adjust to pH 7.2), and the remaining cells were washed with PBS (pH 7.4) and passed through a 40 mm nylon cell strainer. One month post-transfer, the spleens of recipient mice were harvested and analyzed by flow cytometry. The remaining recipient mice were immunized with collagen/CFA emulsion without boosting. Swelling and arthritis score were measured once/wk after the initial immunization and twice/wk after receiving a booster immunization.
Flow cytometry
A single-cell suspension of splenocytes was prepared by use of a manual tissue homogenizer. Whole blood was collected in heparinized tubes. 
Magnetic cell isolation
Single-cell suspensions of the spleen or bone marrow were prepared as described above. 
Griess assay
NO concentrations were determined for cell supernatants collected from CD4 + T or B cell cultures. The nitrite concentration in the culture medium, indicative of NO production, was measured by use of a Griess reagent kit (Invitrogen), according to the manufacturer's specifications. After 30 min of incubation at room temperature, the absorbance was measured at 560 nm. Sodium nitrite was used to prepare a standard curve for calculation of the nitrite concentration in culture medium.
Analysis of systemic cytokine profile
Systemic cytokine profiles of IL-1b, IL-6, IL-17A, TNF-a, and IFN-g were determined by Luminex assay by use of serum collected from CCR2
and WT mice with CIA. Serum cytokine levels were measured with the Bio-Plex Pro mouse Th17 6-plex Luminex panel and analyzed by a Magpix Luminex reader (Bio-Rad Laboratories, Hercules, CA, USA). The 5-parameter regression formula was used to calculate cytokine concentrations from the standard curves.
Adoptive transfer experiment
Collagen-immunized WT or CCR2 2/2 DBA/1J mice were administered with M-MDSCs isolated from the bone marrow of collagen-immunized WT or CCR2 2/2 mice, which were administered 2.50 3 10 5 M-MDSCs by i.v. or 1.5 3 10 6 M-MDSCs by i.p., starting at 14 days postimmunization, followed by treatments every 5 days for a total of 5 treatments/mouse. Swelling and arthritis score were measured, and serum was collected over the course of the disease.
qRT-PCR
The expression of inflammatory cytokine mRNA in the joint tissues was measured by qRT-PCR. In brief, Trizol (Invitrogen) was used to isolate total RNA from the wrist joints of CIA mice, and cDNA was generated by use of the First-Strand cDNA Synthesis SuperScript II RT (Invitrogen). Primers used for the amplification of murine IL-17A, IFN-g, IL-6, IL-1b, TNF-a, and 18s are as follows:
IL-17A forward TCTCTGATGCTGTTGCTGCT , reverse CTCCAGAAGGC-CCTCAGACTAC ; IFN-g forward ACTGGCAAAAGGATGGTGAC , reverse ACCTGTGGG-TTGTTGACCTC ; IL-6 forward TTCCATCCAGTTGCCTTCTT , reverse CAGAATTGCCA-TTGCACAAC ; IL-1b forward GGTCAAAGGTTTGGAAGCAG , reverse TGTGAAATGC-CACCTTTTGA ; TNF-a forward CCTTCACAGAGCAATGACTC , reverse GTCTACTCC-CAGGTTCTCTTC ; 18S forward GACCATAAACGATGCCGACT , reverse GTGAGGTTTCC-CGTGTTGAG qRT-PCR was performed by use of a SYBR Green Master Mix (Bio-Rad Laboratories), and reactions were performed by an iCycler instrument (Bio-Rad Laboratories). The 2 2DDcomparative threshold method was used for data analysis.
Statistical analysis
Numerical data presented in the text and figures are expressed as mean 6 SEM. Statistical significance was established at P # 0.05. For clinical disease assessment, separate general, linear-mixed effects models were used to determine significant differences in arthritis scores and paw swelling, respectively, between the treated and control mice over time. The overall group effect was assessed by use of a LRT. Analyses were conducted by use of SAS v9.2. All other statistical significance was determined by Student's unpaired 2-sample t-test. Morphologic analysis confirmed that the M-MDSCs isolated from CIA mice are immature and monocyte-like, whereas Ly6G + cells are neutrophil-like (Supplemental Fig. 1B ). Fig. 2A and B) . The inhibition of CD4 + T cell proliferation by M-MDSCs was concentration dependent, whereas a T cell:M-MDSC ratio of 1:1 was the most effective, and the inhibitory function was lost at a 4:1 ratio. On the contrary, Ly6G
RESULTS
Collagen immunization results in expansion of
M-MDSC-mediated inhibition of CD4 + T cell proliferation is iNOS and IFN-g dependent but IL-17 independent
+ cells did not suppress T cell proliferation under same conditions but instead, seemed to facilitate T cell proliferation ( Fig. 2A and B) . Together, these data indicate that M-MSDCs, but not Ly6G + cells, are effective suppressors of CD4 + T cell proliferation under conditions of autoimmune arthritis. We next investigated the mechanism by which M-MDSCs inhibit CD4
+ T cell functions in CIA. As NO production is one of the most common suppressive mechanisms used by M-MDSCs [1] , levels of NO in the supernatants of T cell cultures were measured. The amount of NO increased significantly when T cells were cocultured with M-MDSCs but not when T cells were cultured alone or with Ly6G + cells. The sharp increase in NO production was abolished when T cells and M-MDSCs were coincubated in the presence of iNOS inhibitors. Additionally, the increased NO production in the coculture supernatant was diminished by antibody neutralization of IFN-g but not of IL-17 (Fig. 2C) . Consistently, IFN-g levels were significantly increased in cultures of activated T cells alone and activated T cells incubated with M-MDSCs (Supplemental Fig. 2) . Thus, IFN-g produced by activated T cells induces NO production by M-MDSCs. To confirm that the IFN-g-driven production of NO by M-MDSCs was responsible for suppression of CD4 + T cell proliferation, CD4 + T cell proliferation was measured in cocultures with M-MDSCs in the presence of iNOS inhibitors, IFN-g-neutralizing antibody, or IL-17-neutralizing antibody. The inhibition of CD4 + T cell proliferation by M-MDSCs was ablated upon the addition of iNOS inhibitors or anti-IFN-g antibody; however, the anti-IL-17 antibody did not show any effect (Fig.  2D) . This indicates that M-MDSCs but not Ly6G + cells inhibit autologous CD4
+ T cell proliferation in CIA in an iNOS-and IFNg-dependent but IL-17-independent manner.
M-MDSCs inhibit B cell proliferation and antibody production
Autoimmunity results from abnormal B and T cell recognition of self-antigens, which leads to autoantibody production. Therefore, autoantibodies produced by B cells are pivotal to the induction and sustained escalation of autoimmune inflammation seen in many autoimmune diseases, including autoimmune arthritis [17] . (Fig. 3A and B) . To examine whether M-MDSCs affect B cell function, we measured antibody production and found that IgM and IgG production were substantially reduced in cocultures of B cells and M-MDSCs compared with cultures of B cells alone or B cells with Ly6G + cells (Fig. 3C) . In summary, M-MDSCs are capable of suppressing autologous B cell proliferation and inhibiting antibody production in CIA.
M-MDSC-mediated suppression of B cell responses is mediated by iNOS and PGE 2
Identification of the mechanism by which M-MDSCs mediate B cell suppression during CIA is essential for understanding the role of these cells in autoimmune disease. Given the importance of M-MDSC-derived NO in T cell inhibition, the concentration of NO in supernatants of B cell cultures stimulated with CD40L and IL-4 was measured (Fig. 4A) . As observed in T cell cultures, the levels of NO increased significantly when M-MDSCs were added to the B cell cultures. This increase was abolished in the presence of iNOS inhibitors. Levels of NO in cultures of stimulated B cells only or stimulated B cells cultured with Ly6G + cells remained unchanged. Furthermore, the inhibition of B cell proliferation by M-MDSCs was abolished in the presence of iNOS inhibitors (Fig.  4B ). These data demonstrate that M-MDSC-mediated inhibition of B cell proliferation is NO dependent. PGE 2 has been shown to promote MDSC function in the tumor microenvironment, as well as regulate B cell function during infection [21, 22] . Thus, we sought to determine whether PGE 2 was also involved in the M-MDSC-mediated inhibition of B cell function during CIA. The level of PGE 2 was markedly increased in the supernatants of cocultured B cells and M-MDSCs but not in the supernatants of B cells cultured alone, M-MDSC alone, or in the presence of Ly6G + cells (Fig. 4C) . The suppressive effects of M-MDSCs on B cell proliferation were specifically abolished by antagonists of the PGE 2 receptors, EP 2 and EP 4 (Fig. 4D) . These results suggest that M-MDSC-mediated suppression of B cell proliferation is also mediated by PGE 2 production.
M-MDSC suppression of B cells is contact dependent
Whereas the suppressive function of MDSCs on T cells requires cell-cell contact [23] , it is unknown whether this mechanism is required for B cell suppression. To examine this, we performed B cell suppression assays with Transwell inserts. Transwell separation of M-MDSCs from B cells abolished suppression of B cell proliferation by M-MDSCs (Fig. 5A) . Additionally, separation of M-MDSCs from B cells by Transwell eliminated the enhanced production of NO and PGE 2 in cocultures of M-MSDCs and B cells (Fig. 5B and C) . Thus, NO-and PGE 2 -mediated suppression of B cell responses by M-MDSCs is contact dependent.
Administration of M-MDSCs rescues CCR2
2/2 mice from the severe CIA phenotype M-MDSCs were absent from the blood, spleen, and lymph nodes of CCR2 2/2 mice that developed more severe CIA [15] . To determine if the exacerbated CIA phenotype in CCR2 2/2 mice is a result of the absence of peripheral M-MDSCs, we reconstituted M-MDSCs in the periphery of CCR2 2/2 mice. We first assessed the suppressive ability of M-MDSCs derived from CCR2 2/2 mice compared with M-MDSCs derived from WT mice. Both T cell and B cell proliferation was inhibited by M-MDSCs isolated from immunized CCR2 2/2 mice, and the suppressive ability of M-MDSCs isolated from CCR2 2/2 was similar to that of M-MDSCs isolated from WT mice ( Fig. 6C and D) . Therefore, results from the reconstitution experiment would be based on the presence or absence of the M-MDSCs and not the level of their suppressive ability. The reconstitution efficiency of CCR2 2/2 mice with M-MDSCs was monitored 24 h after adoptive transfer. The number of M-MDSCs increased 8.9-fold in the spleen and 3.7-fold in the lymph node in mice receiving M-MDSCs compared with control mice, whereas bone marrow M-MDSCs only increased by 1.1-fold after adoptive transfer (Supplemental Fig. 3) . Thus, peripheral reconstitution of M-MDSCs in CCR2 2/2 mice by adoptive transfer is efficient. Finally, the development of CIA in reconstituted CCR2 2/2 mice was examined. After monitoring disease progression for 45 days, the disease of CCR2 2/2 mice that received M-MDSCs was significantly mitigated as evidenced by decreased clinical arthritis scores (LRT = 14.4; df = 4; P = 0.006) and reduced paw swelling (LRT = 25.5; df = 4; P , 0.0001; Fig. 6A and B). Additionally, CII collagen-specific antibody production was markedly reduced in the serum of mice treated with M-MDSCs (Fig. 6E) . Although not statistically significant, levels of proinflammatory cytokines, such as IL-6 and IL-17, in the serum of M-MDSC-treated mice were decreased compared with the control group (Fig. 6F) . Together, these results suggest that the M-MDSCs absent from the periphery of CCR2 2/2 mice are immunosuppressive during CIA. Therefore, the absence of M-MDSCs from the periphery is one of the mechanisms contributing to the aggravated CIA phenotype of CCR2 2/2 mice.
M-MDSC treatment ameliorates CIA in WT mice
To test whether M-MDSCs have a suppressive function in autoimmune arthritis under WT conditions, the M-MDSC treatment experiment was repeated in WT mice. Compared with control mice, a delay of disease onset and a significant decrease in the progression of arthritis score (LRT = 16.9; df = 4; P = 0.002) and joint swelling (LRT = 30.8; df = 4; P , 0.0001) were observed in the M-MDSC-treated mice ( Fig. 7A and B) . Consistent with the B cell-suppressive function of M-MDSCs, we found a significant decrease in the level of CII collagen-specific antibodies in the serum of mice that received M-MDSC treatment (Fig. 7C) . We also identified decreased expression of proinflammatory cytokines, including IL-6, IL-1b, and IFN-g, in the joints of M-MDSCtreated mice (Fig. 7D) . Thus, administration of M-MDSCs ameliorates CIA in WT mice, suggesting that M-MDSCs can potentially serve as a component of the cell-based therapy against autoimmune arthritis.
DISCUSSION
MDSCs have been reported to regulate autoimmunity by suppressing T cell responses [24] . However, the effect of MDSCs on other cells critically involved in the autoimmune process, such as B cells, is unknown. In the current study, by use of the CIA model of autoimmune arthritis, we demonstrate that M-MDSCs increase in the periphery of WT CIA mice. M-MDSCs isolated from the bone marrow of collagen-immunized WT mice not only suppress CD4 + T cell proliferation but also inhibit proliferation and antibody production by B cells. Interestingly, M-MDSCs are absent from the periphery of CCR2 2/2 mice that develop exacerbated CIA. We hypothesized that the absence of M-MDSCs from the periphery was one of the mechanisms contributing to aggravated MDSCs suppress T cell functions via a number of different mechanisms. NO production through iNOS is one of the major mechanisms of M-MDSC-mediated T cell inhibition [6, 25, 26] . Consistent with data from an EAE model [27] , our data demonstrate that M-MDSC-mediated inhibition of collagenactivated CD4 + T cells is NO dependent. We demonstrate further that the blocking of IFN-g but not IL-17 abolishes M-MDSCmediated CD4 + T cell suppression. This result is in contrast to earlier findings that IL-17 is required for activation of suppressive activity of MDSCs in a tumor model [28] . This discrepancy may be a result of the heterogeneous nature of MDSCs and suggests that the inhibitory functions of MDSCs may be dictated by the particular disease or microenvironment.
B cells are the origin of humoral immunity and precursors of antibody-producing cells. Recent success of anti-B cell therapy against several autoimmune diseases, including RA, confirms a pathologic role for B cells in autoimmune disorders [29] [30] [31] . Thus, it would be of interest to determine if MDSCs can inhibit B cell activities under autoimmune conditions. Our data show that the proliferation of CD40L/IL-4-stimulated B cells isolated from CIA mice is inhibited by autologous M-MDSCs. More importantly, we show that M-MDSCs not only inhibit B cell antibody production in vitro but also reduce serum levels of antigen-specific antibodies in CIA mice after adoptive transfer. To our knowledge, this is the first demonstration that MDSCs are capable of suppressing B cell function in autoimmune disease.
Macrophage-derived PGE 2 was first described as a potent suppressor of splenic B cell colony formation over 30 years ago [32] . Further studies showed a direct effect of PGE 2 on B cell proliferation [33] , initiated via signaling through PGE 2 receptors on the B cell [34] . Based on these findings, we measured the PGE 2 levels in our cell-culture supernatants and found that they were strongly up-regulated in the coculture of B cells and M-MDSCs compared with cultures of B cells or M-MDSCs alone. The addition of Ly6G + cells to the B cell culture did not increase Representative data of at least 3 independent experiments or averaged data from at least 3 independent experiments are shown. **P , 0.01. Together, the different subsets of MDSCs exhibit a diverse range of functions. In our model of autoimmune arthritis, we showed that M-MDSCs but not Ly6G + cells can inhibit T and B cell proliferation. Similar results were also observed in models of tumor and acute airway inflammation. M-MDSCs suppressed anti-tumor-immune responses in a B16 melanoma model, whereas G-MSDCs lacked this inhibitory function [35] . In mice with acute airway inflammation, whereas M-MDSCs (Ly6C antibody recognizes Ly6C and Ly6G myeloid surface antigens, the inhibitory effects observed in these studies could have originated from M-MDSC or G-MDSC subsets or perhaps both [37] . For example, Fujii et al. [38] have recently reported that MDSCs were beneficial to CIA. Similar to our data, they demonstrated CIA amelioration after adoptive transfer of MDSCs. These studies used the total Gr1 + cell population, and therefore, the inhibitory effect cannot be attributed to either subset specifically, leaving the possibility for Ly6G + cell-mediated amelioration of CIA. However, other studies have shown that the depletion of Ly6G + neutrophils by the anti-Ly6G antibody led to reduced CIA severity [39] ; thus, the role of Ly6G + cells in CIA needs further examination. Standardized methods for classifying MDSCs are essential for comparing results from different studies. CCR2 is the major chemokine receptor driving monocyte and macrophage migration [40, 41] . Consistent with the finding that CCR2 2/2 results in exacerbated CIA, clinical trials of anti-CCR2 therapy against RA were not successful [42] [43] [44] . As monocytes and macrophages were thought to be detrimental to inflammatory tissue damage, the underlying mechanism contributing to these unexpected results could not be explained. Our data show that M-MDSCs express high levels of CCR2 and therefore, are absent from the periphery in CCR2 2/2 mice with CIA, as CCR2 is required for the egress of monocytes from the bone marrow [15, 45, 46] . M-MDSCs, isolated from the bone marrow of collagenimmunized CCR2 mice. Furthermore, M-MDSC treatment is beneficial to CIA in WT mice, although it cannot eliminate the disease completely. Together, our results suggest that the failure of anti-CCR2 therapy in RA patients may be a result of disruption of M-MDSC regulatory functions.
In summary, we demonstrate that M-MDSCs are capable of suppressing T and B cell function, as well as disease progression in CIA, suggesting that the targeting of MDSCs can provide a potential therapeutic approach against autoimmune disease. However, this objective is complicated by evidence of regulatory and pathogenic roles for monocytes and macrophages during inflammation [47] [48] [49] . Whereas the targeting of MDSCs may be a potential therapeutic approach in treating autoimmune disease, careful consideration of different MDSC subsets and corresponding functions in autoimmunity is critical to the design of successful therapies. 
